Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy

Details

Ressource 1Download: serval:BIB_330436096753.P001 (148.70 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_330436096753
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy
Journal
Clinical Infectious Diseases
Author(s)
Cometta  A., Kern  W. V., De Bock  R., Paesmans  M., Vandenbergh  M., Crokaert  F., Engelhard  D., Marchetti  O., Akan  H., Skoutelis  A., Korten  V., Vandercam  M., Gaya  H., Padmos  A., Klastersky  J., Zinner  S., Glauser  M. P., Calandra  T., Viscoli  C.
ISSN
1537-6591 (Electronic)
Publication state
Published
Issued date
08/2003
Volume
37
Number
3
Pages
382-9
Notes
Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Aug 1
Abstract
This prospective, double-blind trial assessed whether the addition of a glycopeptide would be able to reduce the time to defervescence in neutropenic patients with cancer who had persistent fever 48-60 h after the initiation of empirical piperacillin-tazobactam monotherapy. Of 763 eligible patients, 165 with persistent fever were randomized to receive piperacillin-tazobactam therapy plus either vancomycin therapy or placebo. Defervescence was observed in 82 (95%) of 86 patients in the vancomycin group and in 73 (92%) of 79 patients in the placebo group (P=.52). The distributions of the time to defervescence were not statistically significant between the 2 groups (estimated hazard ratio, 1.03; 95% confidence interval, 0.75-1.43; P=.75). The number of additional episodes of gram-positive bacteremia and the percentage of patients for whom amphotericin B was empirically added to their therapy regimen were also similar in both groups. This study failed to demonstrate that the empirical addition of vancomycin therapy to the treatment regimen is of benefit to persistently febrile neutropenic patients with cancer.
Keywords
Adolescent Adult Aged Child Child, Preschool Double-Blind Method Fever/chemically induced/*drug therapy Humans Middle Aged Neoplasms/complications/*drug therapy/physiopathology Neutropenia/etiology Penicillanic Acid/*adverse effects/analogs & derivatives/therapeutic use Piperacillin/*adverse effects/therapeutic use Treatment Outcome Vancomycin/*therapeutic use
Pubmed
Web of science
Open Access
Yes
Create date
25/01/2008 14:31
Last modification date
25/09/2019 7:08
Usage data